Achaogen Inc (AKAO.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2009||Independent Chairman of the Board|
|56||2018||President, President - R&D and Director|
|47||2018||Chief Executive Officer, Director|
|42||2016||Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer|
|41||2017||Senior Vice President, Chief Scientific Officer|
- BRIEF-Achaogen Q1 loss per share $1.06
- BRIEF-Achaogen Says FDA Advisory Committee Voted In Favor Of Plazomicin For Urinary Tract Infections
- BRIEF-Achaogen Stock Trading Halted Today
- BRIEF-Achaogen Says FDA to Review Plazomicin By June 25
- BRIEF-Robert Duggan Reports 14.2 Pct Stake In Achaogen Inc As Of March 12 Compared To A Stake Of 13.2 Pct As Of Dec 6